SAN DIEGO, Jan. 4, 2016 /PRNewswire/ -- GenomeDx Biosciences today announced that seven abstracts featuring the Decipher Genomic Resource Information Database (Decipher GRID™) and Decipher® Prostate Cancer Classifier will be presented at the 2016 Genitourinary Cancers Symposium, held Jan. 7-9 in San Francisco.
The presentations will all be delivered during Session A from 11:30 a.m. to 1 p.m. PST and from 5:15 p.m. to 6:45 p.m. PST on Thursday, Jan. 7. A presentation featuring Decipher GRID has also been recognized as a top abstract of the symposium.
The 2016 Genitourinary Cancers Symposium is cosponsored by the American Society of Clinical Oncology (ASCO), the American Society for Therapeutic Radiology and Oncology (ASTRO), and the Society of Urologic Oncology (SUO).
Presentations
Title: Validation of the Decipher prostate cancer classifier for predicting 10-year postoperative metastasis from analysis of diagnostic needle biopsy specimens
Presenter: Eric Klein, M.D., chairman, Glickman Urological and Kidney Institute at Cleveland Clinic
Abstract Number: 59
Poster Number: C19
Recognized as Top Abstract
Title: Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk
Presenter: Robert Den, M.D., assistant professor of radiation oncology and cancer biology at Thomas Jefferson University
Abstract Number: 12
Poster Number: A14
Title: Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy
Presenter: Robert Den, M.D., assistant professor of radiation oncology and cancer biology at Thomas Jefferson University
Abstract Number: 4
Poster Number: A6
Title: The frequency of druggable targets in localized prostate cancer: initial analysis from the Decipher GRID
Presenter: Nicholas Erho, GenomeDx Biosciences
Abstract Number: 98
Poster Number: E14
Title: The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy
Presenter: Ashley Ross, M.D., Ph.D., associate professor of urology and oncology, Johns Hopkins School of Medicine
Abstract Number: 256
Poster Number: L5
Title: Development and validation of an ADT resistance signature that predicts adjuvant hormone treatment failure
Presenter: R. Jeffrey Karnes, M.D., associate professor and vice chair in Urology at Mayo Clinic
Abstract Number: 106
Poster Number: E22
Title: Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility
Presenter: Mohammed Alshalalfa, Ph.D., GenomeDx Biosciences
Abstract Number: 303
Poster Number: N8
About Decipher® Prostate Cancer Classifier
Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by radiation oncologists and urologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. Decipher offers valuable insight that is distinct from clinical measures of risk including PSA and Gleason score. Studies of thousands of patients from leading cancer centers, published in more than 20 peer-reviewed journals, demonstrate that Decipher can accurately predict metastatic disease, identify patients most likely to benefit from therapeutic intervention, and lead to significant cost-savings for healthcare systems by reducing unnecessary procedures. Decipher is covered by Medicare and multiple private insurance plans in the US representing over 190 million covered lives.
Learn more at www.DecipherTest.com
About Decipher GRID™
The Decipher Genomic Resource Information Database (Decipher GRID™) is the world's largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GRID unifies a patient's whole genome data with clinical outcomes from thousands of patients evaluated with Decipher®, providing unprecedented data sharing capabilities. Ultimately, GRID will use patient tumor genomic information to better match an individual to a targeted therapy with the highest likelihood of providing a benefit. The Decipher GRID program is rapidly expanding as major cancer centers partner with GenomeDx to access the database to advance their understanding of urologic cancers through the analysis of large amounts of genomic data.
Learn more at www.DecipherGRID.com
About GenomeDx Biosciences
GenomeDx Biosciences is a genomic information company changing the landscape of urologic cancer patient care with innovative genomic solutions that empower physicians and patients to make more informed decisions about patient treatment. Using advanced cloud-based bioinformatics to mine vast amounts of genomic data, the company develops and commercializes proprietary clinical tests that provide actionable information to answer key clinical questions in patient management. GenomeDx's Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. In partnership with leading medical centers, GenomeDx is building Decipher GRID™, the world's largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GenomeDx is based in San Diego and Vancouver, British Columbia.
Learn more at www.GenomeDx.com
Media Contact:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com
SOURCE GenomeDx Biosciences